The Medical Letter on Drugs and Therapeutics (commonly referred to as The Medical Letter) is a scientific journal providing evaluations of drugs. It has a print and electronic circulation of well over 450,000 subscribers in 125 countries worldwide.
It is published biweekly (26 issues/year) in several languages: English (US and Canadian editions), French (Canadian and European editions), Italian, Japanese, and Spanish.
The Medical Letter is published by The Medical Letter, Inc., which also publishes the monthly Treatment Guidelines from The Medical Letter.
Articles for The Medical Letter are drafted by either an editor or external consultant using both published and available unpublished studies that are reviewed for methodological rigor with special attention to the results of clinical trials. A preliminary draft is circulated to every member of the advisory board and 10-20 other investigators with relevant clinical or experimental experience with the article's topic. Drafts are also provided to the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC), all first authors of articles cited in the text, and to the pharmaceutical companies that manufacture the drug, or similar compounds. The evaluation of each drug includes a discussion of its efficacy, side effects, and a comparison with older, more established agents. The final version of the paper includes comments from the reviewers and is checked and edited for accuracy and readability.
It is published biweekly (26 issues/year) in several languages: English (US and Canadian editions), French (Canadian and European editions), Italian, Japanese, and Spanish.
The Medical Letter is published by The Medical Letter, Inc., which also publishes the monthly Treatment Guidelines from The Medical Letter.
Articles for The Medical Letter are drafted by either an editor or external consultant using both published and available unpublished studies that are reviewed for methodological rigor with special attention to the results of clinical trials. A preliminary draft is circulated to every member of the advisory board and 10-20 other investigators with relevant clinical or experimental experience with the article's topic. Drafts are also provided to the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC), all first authors of articles cited in the text, and to the pharmaceutical companies that manufacture the drug, or similar compounds. The evaluation of each drug includes a discussion of its efficacy, side effects, and a comparison with older, more established agents. The final version of the paper includes comments from the reviewers and is checked and edited for accuracy and readability.
0 comments:
Post a Comment